As prostate cancer (PCa) is one of the most frequent causes of cancer-related mortality in western societies [7], even greater expectations are fuelled by studies on prostate-specific membrane antigen (PSMA) inhibitors labelled with diagnostic and therapeutic radionuclides. Here, FOLH1 is linked to prostate carcinoma.